The trial will test the safety and efficacy of a new vaccine intended to prevent and slow the progression of Alzheimer’s disease (AD). The trial represents the culmination of nearly 20 years of research led by Howard L. Weiner, MD, co-director of the Ann Romney Center for Neurologic Diseases.
Experts from the Brigham’s Division of Cardiovascular Medicine recently presented cutting-edge research advances at the American Heart Association’s 2021 Scientific Sessions. Presentations included late-breaking clinical trial updates, a new study on coronary artery disease treatments, and findings on SGLT-2 inhibitors use in heart failure patients.
Your contribution will aid our efforts on every front as we work together to defeat COVID-19, care for our patients and families in their hours of greatest need, and emerge stronger than ever.Give Now
We are inspired by our patients’ courage, our caregivers’ compassion, and our scientists’ curiosity—all fueled by our donors’ generosity.
Imagine what we can do together.